This article summarizes published peptide research. All content is presented for research reference only and is not intended as medical advice or guidance for personal peptide use. Products referenced are research compounds — not for human consumption, diagnostic or therapeutic application.

Tesamorelin is the only GHRH analog that made it through FDA approval (for HIV-associated lipodystrophy, under the brand Egrifta). That's not a minor detail. It means this compound has a clinical evidence base that most peptides can only dream of.

GHRH vs GHRP: the distinction that matters

Before we get into tesamorelin specifically, you need to understand the two categories of GH peptides. GHRPs (like [[Ipamorelin|17]]) tell the pituitary to release stored GH. GHRHs (like tesamorelin) tell the pituitary to manufacture and release GH. Different signal, different result.

GHRH analogs produce more physiological GH secretion patterns. They amplify your natural pulsatile GH rhythm rather than overriding it. The amplitude of each pulse goes up, but the timing stays natural. This is closer to how young, healthy GH levels look.

What tesamorelin does

Tesamorelin is a synthetic analog of human GHRH (growth hormone-releasing hormone) with a trans-3-hexenoic acid modification that improves stability and half-life. It binds to GHRH receptors on pituitary somatotrophs and in studies demonstrates stimulation of both the synthesis and release of GH.

The primary clinical indication was visceral adipose tissue (VAT) reduction. In the Phase III LIPO trials, tesamorelin reduced trunk fat by 15-18% over 26 weeks in participants with HIV-associated lipodystrophy (Falutz et al., JAMA, 2007). These participants had abnormal visceral fat accumulation, and in the trials tesamorelin specifically targeted this compartment.

Beyond the HIV population, research suggests tesamorelin's effects extend to general visceral fat reduction, cognitive improvement in older adults (Baker et al., JAMA Neurology, 2012), and improved inflammatory markers.

The visceral fat angle

Visceral fat (the fat surrounding your organs, inside the abdominal cavity) is metabolically different from subcutaneous fat (the fat under your skin). Visceral fat is more inflammatory, more insulin-resistant, and more associated with cardiovascular risk.

Tesamorelin appears to preferentially target visceral fat. In the LIPO trials, visceral fat decreased significantly while subcutaneous fat changes were minimal. This makes tesamorelin particularly interesting for people carrying abdominal visceral fat even at relatively normal body weight.

Cognitive effects

An unexpected finding: Baker et al. (2012) studied tesamorelin in 137 healthy older participants and reported changes in executive function and verbal memory. The hypothesis: GH and IGF-1 have direct effects on hippocampal function and neuroplasticity. Restoring GH levels through GHRH is discussed in research in the context of cognitive maintenance in aging. Phase III trials for this indication haven't been completed, but the preliminary data is intriguing.

Dosing

FDA-approved dose: 2mg subcutaneously daily. Research protocols sometimes vary between 1-2mg daily. Unlike GHRPs that are often dosed multiple times per day, tesamorelin is once daily, typically in the morning on an empty stomach.

[[Tesamorelin|18]] comes in vial format (multiple size options). Reconstitute with bacteriostatic water. Course length in clinical trials: 26-52 weeks continuously.

Stacking with Ipamorelin

The GHRH + GHRP combination is well-researched. Tesamorelin (GHRH) tells the pituitary to produce more GH. [[Ipamorelin|17]] (GHRP) tells it to release what it's made. Together, GH output is significantly higher than either compound alone. This synergistic approach is one of the most extensively documented GH peptide protocols.

Side effects

From the clinical trial database: injection site reactions (redness, itching) in about 10-15%. Joint pain in 5-10% (GH-mediated, usually mild). Peripheral edema (mild swelling, typically in hands/feet) in about 5%. Carpal tunnel symptoms in a small percentage.

These are GH-related side effects, not tesamorelin-specific. They tend to be milder than what's seen with exogenous GH because the GH release pattern is more physiological.

Who this is for

If visceral abdominal fat is a specific concern. If you want a GHRH-based approach to GH optimization rather than GHRP. If the FDA-approved clinical evidence base matters to you. Or if you want to stack with ipamorelin for the synergistic GH protocol.

Check out [[Tesamorelin|18]]. Questions about dosing or stacking? Reach out to us.

This article is for educational purposes. Peptides are intended for research use. Content is provided as research reference material.